Related Experiment Video
Updated: Sep 25, 2025

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Hypokinetic hypertrophic cardiomyopathy: clinical phenotype, genetics, and prognosis
Yishay Wasserstrum1,2, José M Larrañaga-Moreira3, Cristina Martinez-Veira3
1Leviev Heart Center, Sheba Medical Center in Tel-Ha'Shomer, Ramat-Gan, Israel.
Insights
Hypertrophic cardiomyopathy with reduced ejection fraction (HCMr) affects nearly 3% of patients and is linked to worse outcomes. Identifying predictors like atrial fibrillation and specific genetic variants is crucial for managing this condition.
Area of Science:
- Cardiology
- Genetics
- Heart Failure Research
Background:
- Hypertrophic cardiomyopathy (HCM) typically presents with preserved ejection fraction.
- However, a subset of HCM patients develops reduced ventricular function (HCMr), associated with poorer prognosis.
- Understanding HCMr development and its impact is critical for patient management.
Purpose of the Study:
- To characterize the phenotype, genetic factors, and clinical events preceding the development of HCMr.
- To identify predictors for HCMr development in a large HCM cohort.
- To assess the clinical outcomes associated with HCMr.
Main Methods:
- A registry of 1328 HCM patients from Spain and Israel was analyzed.
- Competing-risk analysis identified factors associated with HCMr development.
- Genetic data were collected, and clinical events preceding HCMr were reviewed.
- Outcomes, including mortality and need for ventricular assist device (VAD)/heart transplantation, were assessed.
Main Results:
- HCMr was present at baseline in 2.8% and developed during follow-up in 3.5% of patients.
- Factors predicting HCMr included younger age at diagnosis, poor functional class, ventricular arrhythmia, atrial fibrillation, pacemaker implantation, and LVEF ≤55%.
- LV obstruction was associated with a lower risk of HCMr.
- Genetic testing revealed pathogenic variants in 72% of HCMr patients, most commonly in myosin binding protein C.
- HCMr was associated with a significantly higher risk of mortality or VAD/heart transplantation.
Conclusions:
- Reduced ejection fraction in HCM (HCMr) is linked to heart failure and adverse outcomes.
- Events like arrhythmias and device implantation may precede or result from adverse remodeling in HCMr.
- Further research is needed to predict and prevent the development of HCMr.
Aims:
To describe the phenotype, genetics, and events associated with the development of hypertrophic cardiomyopathy (HCM) with reduced ventricular function (HCMr). Heart failure in HCM is usually associated with preserved ejection fraction, yet some HCM patients develop impaired systolic function that is associated with worse outcomes.
Methods And Results:
Our registry included 1328 HCM patients from two centres in Spain and Israel. Patients with normal baseline ventricular function were matched, and a competing-risk analysis was performed to find factors associated with HCMr development. Patient records were reviewed to recognize clinically significant events that occurred closely before the development of HCMr. Genetic data were collected in patients with HCMr. A composite of all-cause mortality or ventricular assist device (VAD)/heart transplantation was assessed according to ventricular function. Median age was 56, and 34% were female patients. HCMr at evaluation was seen in 37 (2.8%) patients, and 46 (3.5%) developed HCMr during median follow up of 9 years. HCMr was associated with younger age of diagnosis, poor functional class, and ventricular arrhythmia. Atrial fibrillation, pacemaker implantation, and baseline left ventricular ejection fraction (LVEF) of ≤55% were significant predictors of future HCMr development, while LV obstruction predicted a lower risk. Genetic testing performed in 53 HCMr patients, identifying one or more pathogenic variant in 38 (72%): most commonly in myosin binding protein C (n = 20). Six of these patients had an additional pathogenic variant in one of the sarcomere genes. Patients with baseline HCMr had a higher risk (hazard ratio 6.4, 4.1-10.1) for the composite outcome and for the individual components. Patients who developed HCMr in the course of the study had similar mortality but a higher rate of VAD/heart transplantation compared with HCM with normal LVEF.
Conclusions:
Hypertrophic cardiomyopathy with reduced ejection fraction is associated with heart failure and poor outcome. Arrhythmia, cardiac surgery, and device implantation were commonly documented prior to HCMr development, suggesting they may be either a trigger or the result of adverse remodelling. Future studies should focus on prediction and prevention of HCMr.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy II: Dilated Cardiomyopathy
Pathophysiology of Heart Failure
Heart Failure II: Pathophysiology

